• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.57% Nasdaq Up2.12%

    More On NVDL



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Novadel Pharma Inc. (NVDL)

    -Other OTC
    0.01 Up 0.00(11.11%) Jun 28, 11:19AM EDT
    |Pre-Market : NaN
    ProfileGet Profile for:
    Novadel Pharma Inc.
    1200 Route 22 East
    Suite 2000
    Bridgewater, NJ 08807
    United States - Map
    Phone: 908-203-4640
    Fax: 908-203-4744
    Website: http://www.novadel.com

    Index Membership:N/A
    Industry:Drug Delivery
    Full Time Employees:N/A

    Business Summary 

    NovaDel Pharma Inc., a specialty pharmaceutical company, develops oral spray formulations for marketed pharmaceuticals. The company’s proprietary technology enables delivery of drugs into the bloodstream leading to onset of action and patient benefits. Its oral spray candidates target angina, insomnia, erectile dysfunction, migraine headaches, and nausea. NovaDel Pharma’s marketed products include NitroMist for acute relief of an attack of angina pectoris, or acute prophylaxis of angina pectoris, due to coronary artery disease; and ZolpiMist for short-term treatment of insomnia. The company’s product candidates comprise Duromist, which is in preclinical development for erectile dysfunction; Zensana, which is in preclinical development for nausea; NVD-201, an oral spray formulation of sumatriptan in Phase 2/3 clinical trial to treat migraine headache; NVD-301, an oral spray formulation of midazolam in preclinical stage for the treatment of sedation during diagnostic, therapeutic, and endoscopic procedures; and ZolpiMist in Phase 1 clinical trial to treat middle of the night awakening. It has strategic license agreements with Talon Therapeutics, Inc., Kwang Dong Pharmaceuticals, and BioAlliance Pharma SA to develop and market Zensana; Manhattan Pharmaceuticals, Inc. for the company’s oral spray technology to deliver propofol for pre-procedural sedation; and Velcera Pharmaceuticals, Inc. for veterinary applications for marketed veterinary drugs. NovaDel Pharma also has agreements with Mist Acquisition, LLC, for the manufacturing and commercialization of the NitroMist lingual spray version of nitroglycerine; and ECR Pharmaceuticals Company, Inc. to manufacture and commercialize ZolpiMist. The company was formerly known as Flemington Pharmaceutical Corporation and changed its name to NovaDel Pharma Inc. in October 2002. NovaDel Pharma Inc. was founded in 1982 and is headquartered in Bridgewater, New Jersey.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Novadel Pharma Inc.

    Key Executives 
    Mr. Steven B. Ratoff , 73
    Chairman, Chief Exec. Officer, Pres, Interim Chief Financial officer and Sec.
    Dr. Charles B. Nemeroff M.D., Ph.D., 66
    Chairman of Scientific Advisory Board, Chairman of Compensation Committee, Member of Audit Committee and Member of Corp. Governance & Nominating Committee
    Susan H. Griffin ,
    Director of Investor Relations
    Dr. Frank Blondino Ph.D.,
    Exec. Director of Formulation & Process Devel.
    Amounts are as of Dec 31, 2010 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.